Why Is MADRIGAL PHARMACEUTI (MDGL) Stock Moving Today?

MDGL stock rose 5.39% to $539.75 on Friday, driven by a positive analyst upgrade and strong earnings results. The stock opened at $510.14 and reached an intraday high of $539.89 at 1:45 PM ET before closing at $539.50. The move came as Wolfe Research upgraded the stock to Outperform and set a $605 price target.

What Happened

Madrigal Pharmaceuticals stock climbed on the back of a recent upgrade from Wolfe Research, which cited the company’s strong earnings and growth potential. The stock beat expectations in its second-quarter report, with earnings per share of $(1.99) versus an estimate of $(2.50) and revenue of $364.252 million versus an estimate of $353.178 million. Barclays also maintained its Overweight rating but lowered its price target to $962. These developments, combined with positive commentary from The Motley Fool about Rezdiffra’s long-term growth potential, contributed to the stock’s rally.

What The Data Shows

The stock has traded between $393.61 and $615.00 over the past 52 weeks and is currently trading near the upper end of that range. It has posted 22 fresh 52-week highs on August 26. The session saw volume of 0.1 million shares, or 0.3 times the 3-month daily average. Despite the recent rise, the stock remains unprofitable with a trailing twelve-month EPS of -14.22 and a net margin of -25.3%. Recent insider transactions show three sales totaling $2.2 million in the last 90 days, with the most recent on August 20.

What To Watch

Madrigal Pharmaceuticals does not have an upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any further developments in its drug pipeline or regulatory approvals.